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Primary CNS lymphoma and HLA class I and II alleles in a
German cohort of immunocompetent patients
Abstract
Human leukocyte antigens (HLA) are involved in the regulation of immune response to infection and in
malignant transformation. Several HLA alleles are associated with immunological or malignant
diseases. The aim of the present study was to evaluate a potential association of HLA class I and II
alleles with primary central nervous system lymphoma (PCNSL) in immunocompetent patients. We
therefore analyzed particular HLA-A, HLA-B and HLA-DRB1 alleles in 82 PCNSL patients and
compared the data to those in 327 population controls. No significant difference between these two
groups was found using Pearson's chi(2) test. These data do not support the hypothesis that HLA alleles
play a major role in the pathogenesis of PCNSL.
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Abstract    
Human leukocyte antigens (HLA) are involved in the regulation of immune response to 
infection and in malignant transformation. Several HLA alleles are associated with 
immunological or malignant diseases. The aim of the present study was to evaluate a potential 
association of HLA class I and II alleles with primary central nervous system lymphoma 
(PCNSL) in immunocompetent patients. We therefore analyzed particular HLA-A, HLA-B 
and HLA-DRB1 alleles in 82 PCNSL patients and compared the data to those in 327 
population controls. No significant difference between these two groups was found using 
Pearson’s chi2 test. These data do not support the hypothesis that HLA alleles play a major 
role in the pathogenesis of PCNSL.  
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Introduction 
Primary central nervous system lymphoma (PCNSL) is an aggressive subtype of non-
Hodgkin’s lymphoma (NHL) arising within the central nervous system (CNS) in the absence 
of systemic manifestations. The majority of these tumors are diffuse large B-cell lymphomas 
(DLBCL) derived from germinal center B cells [1]. PCNSL is known to be associated with 
immunodeficiency, for example, due to the acquired immunodeficiency syndrome (AIDS) or 
to long-term immunosuppressive therapy [2, 3]. In immunocompetent patients, an association 
of PCNSL with the germline genetic variant methyltetrahydrofolate homocysteine S-
methyltransferase (MTR) c.2756A>G (p.D919G) has been reported [4].  
Human leukocyte antigens (HLA) class I and II play an important role in regulating the 
immune response to infection and malignant transformation. Certain HLA alleles are 
associated with autoimmune diseases such as ankylosing spondylitis (B27) and multiple 
sclerosis (DR2, DQ3). Furthermore, HLA alleles have been reported to be associated with 
nasopharyngeal, colorectal and thyroid carcinoma [5, 6]. Findings are less clear for primary 
brain tumors such as glioma and meningioma [7, 8]. In malignant lymphoma, an association 
between HLA alleles and Hodgkin`s lymphoma, HTLV-1-associated T-cell-lymphoma and 
mycosis fungoides has been described [9-12]. However, the relevance of HLA alleles for the 
development of PCNSL has not been investigated yet. 
 
Patients and methods 
Between 08/2000 and 09/2002 a series of 82 consecutive immunocompetent PCNSL patients 
of Caucasian origin recruited for the ongoing German multicenter phase IV trial (G-PCNSL-
SG-1) were evaluated. The aim of the G-PCNSL-SG-1 study was to analyze the value of 
whole brain radiotherapy in first-line therapy of patients with PCNSL. Inclusion criteria for 
the G-PCNSL-SG-1 study was a newly diagnosed and histologically or cytologically (in the 
cerebrospinal fluid) confirmed PCNSL in an immunocompetent patient with an adequate renal 
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and bone marrow function. Exclusion criteria were systemic manifestation of NHL and 
additional malignancies as well as immunodeficiency or concomitant immunosuppressive 
therapy. The median age of patients analysed for the present study was 59 years (range 18-76 
years), 48% were female. Control blood samples were obtained from 327 healthy German 
Caucasian blood donors at the Department of Transfusion Medicine and at the Section of 
Transplantation-Immunology and Immunohematology, University of Tuebingen Medical 
Center. EDTA blood was drawn from all patients and controls after informed consent and 
stored at -20°C until analysis. The study was approved by the respective local ethics 
committees. 
Genomic DNA was isolated from peripheral blood cells applying the QIAamp® Blood Kit 
(Qiagen, Chatsworth, CA, USA) [13]. The LiPA HLA-A/v1.5/010331, HLA-B/v1.5/010331 
and HLA-DRB/v5.5/010331 sequence specific oligonucleotide (SSO) typing kits 
(Innogenetics, Brussels, Belgium) were applied for low/medium resolution HLA typing of the 
HLA-A, -B, -DRB1 alleles.  
For statistical analysis HLA allele frequencies were determined in the patient group and 
compared to those of the local control sample. Comparisons between patients and control 
individuals were performed by Pearson’s chi2 test (degrees of freedom = 1) with Yates’ 
correction for small sample sizes where applicable. Threshold was defined with two-sided α = 
0.05. All statistical calculations were performed using Statistical Analysis Software (SAS) 
Program for Windows, version 6.11. 
 
Results and discussion 
The status of particular HLA-A, -B and -DRB1 alleles was analyzed in 82 immunocompetent 
patients with PCNSL and 327 healthy control individuals in order to investigate whether there 
are associations between HLA alleles and PCNSL. The observed frequencies of the HLA 
alleles analyzed in the patient and the control sample are given in Table 1. Statistical analysis 
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did not reveal any significant differences in the frequencies of HLA-A, HLA-B and HLA-
DRB1 alleles between these two groups.  
Our results are limited by the sample size of PCNSL patients. However, a major effect of the 
analyzed HLA alleles on the development of PCNSL in this patient collective seems unlikely. 
The presented data therefore do not support the hypothesis of an involvement of HLA alleles 
in the pathogenesis of PCNSL in immunocompetent patients. Additional studies may be 
required to increase the power of this conclusion, and studies on immunocomprized and 
immunodeficient patients as well as the analysis of further HLA alleles may be added.  
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Table 1  Human leukocyte antigen (HLA) allele frequencies in patients with primary central nervous 
system lymphoma (n = 82) and healthy control individuals (n = 327) 
HLA-A HLA-B HLA-DRB1 
allele patients controls χ2; P allele patients controls χ2; P allele patients controls χ2; P 
01 0.30 0.29 0.165; 0.685a   07 0.27 0.24 0.414; 0.520a 01 0.17 0.24 0.377; 0.539a
02 0.48 0.48 0.184; 0.668a   
   
 
   
   
  
   
   
   
   
   
   
08 0.24 0.20 0.390; 0.532a 03 0.21 0.22 0.091; 0.762a
03 0.18 0.30 2.344; 0.126a 13 0.02 0.04 0.187; 0.665a 04 0.15 0.27 1.849; 0.174a
11 0.12 0.13 0.003; 0.953 14 0.02 0.05 0.294; 0.588a 07 0.15 0.18 0.00; 0.995 
23 0.06 0.03 0.902; 0.342a 15 0.18 0.14 0.745; 0.388a 08 0.08 0.08 0.112; 0.738a
24 0.11 0.16 0.405; 0.524a 18 0.07 0.09 0.040; 0.841a 09 0.0 0.02 0.222; 0.638a
25 0.02 0.04 0.051; 0.822a 27 0.12 0.09 0.393; 0.531a 10 0.01 0.02 0.008; 0.928 
26 0.07 0.09 0.003; 0.957a 35 0.18 0.25 1.068; 0.301a 11 0.21 0.22 0.127; 0.722a
29 0.02 0.05 0.304; 0.581a 37 0.01 0.02 0.060; 0.807a 12 0.06 0.03 1.112; 0.292a
30 0.01 0.04 0.626; 0.429a 38 0.05 0.07 0.267; 0.606a 13 0.29 0.26 1.138; 0.286a
31 0.06 0.05 0.171; 0.679a 39 0.02 0.04 0.187; 0.665a 14 0.04 0.08 0.734; 0.392a
32 0.12 0.09 0.963; 0.326a 40 0.05 0.11 1.979; 0.159a 15 0.31 0.27 1.645; 0.200a
33 0.01 0.03 0.102; 0.750a 41 0.02 0.01 0.322; 0.570a 16 0.06 0.16 2.942; 0.086a
34 0.0 0.0  42 0.0 0.0  NAb 
 
 
 
0.20 0.02  
66 0.02 0.01 0.905; 0.342a 44 0.26 0.20 1.147; 0.284a     
68 0.13 0.11 0.381; 0.537a 45 0.0 0.0      
69 0.0 0.01 0.010; 0.920a 46 0.0 0.0      
NAb 
 
 
 
 
0.24 0.08  47 0.01 0.01 0.066; 0.798     
    48 0.0 0.0      
    49 0.02 0.02 0.132; 0.716     
    50 0.01 0.03 0.418; 0.518a     
    51 0.13 0.12 0.016; 0.898a     
    52 0.02 0.01 0.099; 0.753a     
    53 0.01 0.01 0.00; 0.995     
    54 0.0 0.0      
    55 0.0 0.03 1.411; 0.235a     
    56 0.01 0.01 0.00; 0.995     
    57 0.06 0.06 0.007; 0.931     
    58 0.01 0.01 0.066; 0.798     
    59 0.0 0.0      
    67 0.0 0.0      
    NAb 0.13 0.04      
 
a Yates correction for small sample size; b not assessable 
Allele frequencies are given as relative amount. 
P is the result of Pearson`s chi2 test.  
 
